LAVA Therapeutics N.V. Statistics
Share Statistics
LAVA Therapeutics N.V. has 26.29M shares outstanding. The number of shares has increased by 0.01% in one year.
| Shares Outstanding | 26.29M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 14.17M |
| Failed to Deliver (FTD) Shares | 7.42K |
| FTD / Avg. Volume | 6.27% |
Short Selling Information
The latest short interest is 26.44K, so 0.1% of the outstanding shares have been sold short.
| Short Interest | 26.44K |
| Short % of Shares Out | 0.1% |
| Short % of Float | 0.19% |
| Short Ratio (days to cover) | 0.41 |
Valuation Ratios
The PE ratio is -1.01 and the forward PE ratio is -0.91.
| PE Ratio | -1.01 |
| Forward PE | -0.91 |
| PS Ratio | 6.24 |
| Forward PS | 2.2 |
| PB Ratio | 0.83 |
| P/FCF Ratio | -1.06 |
| PEG Ratio | n/a |
Enterprise Valuation
LAVA Therapeutics N.V. has an Enterprise Value (EV) of 4.32M.
| EV / Earnings | -0.1 |
| EV / Sales | 0.64 |
| EV / EBITDA | -0.11 |
| EV / EBIT | -0.1 |
| EV / FCF | -0.11 |
Financial Position
The company has a current ratio of 6.62, with a Debt / Equity ratio of 0.1.
| Current Ratio | 6.62 |
| Quick Ratio | 6.62 |
| Debt / Equity | 0.1 |
| Total Debt / Capitalization | 9.36 |
| Cash Flow / Debt | -7.38 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.82% and return on capital (ROIC) is -75.74%.
| Return on Equity (ROE) | -0.82% |
| Return on Assets (ROA) | -0.41% |
| Return on Capital (ROIC) | -75.74% |
| Revenue Per Employee | 182.95K |
| Profits Per Employee | -1.13M |
| Employee Count | 37 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 279.00K |
| Effective Tax Rate | -0.01 |
Stock Price Statistics
The stock price has increased by -40.85% in the last 52 weeks. The beta is 0.48, so LAVA Therapeutics N.V.'s price volatility has been higher than the market average.
| Beta | 0.48 |
| 52-Week Price Change | -40.85% |
| 50-Day Moving Average | 1.41 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 35.93 |
| Average Volume (20 Days) | 118.35K |
Income Statement
In the last 12 months, LAVA Therapeutics N.V. had revenue of 6.77M and earned -41.97M in profits. Earnings per share was -1.57.
| Revenue | 6.77M |
| Gross Profit | 3.29M |
| Operating Income | -43.25M |
| Net Income | -41.97M |
| EBITDA | -40.42M |
| EBIT | -43.25M |
| Earnings Per Share (EPS) | -1.57 |
Balance Sheet
The company has 44.23M in cash and 6.31M in debt, giving a net cash position of 37.92M.
| Cash & Cash Equivalents | 44.23M |
| Total Debt | 6.31M |
| Net Cash | 37.92M |
| Retained Earnings | -148.07M |
| Total Assets | 83.36M |
| Working Capital | 66.34M |
Cash Flow
In the last 12 months, operating cash flow was -38.97M and capital expenditures -730.00K, giving a free cash flow of -39.70M.
| Operating Cash Flow | -38.97M |
| Capital Expenditures | -730.00K |
| Free Cash Flow | -39.70M |
| FCF Per Share | -1.49 |
Margins
Gross margin is 48.56%, with operating and profit margins of -638.99% and -620.09%.
| Gross Margin | 48.56% |
| Operating Margin | -638.99% |
| Pretax Margin | -615.97% |
| Profit Margin | -620.09% |
| EBITDA Margin | -597.09% |
| EBIT Margin | -638.99% |
| FCF Margin | -586.53% |
Dividends & Yields
LVTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -161.86% |
| FCF Yield | -155.72% |
Analyst Forecast
The average price target for LVTX is $2, which is 106.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $2 |
| Price Target Difference | 106.2% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | -2.57 |
| Piotroski F-Score | 2 |